eye care News
-
Metrofocus
ADVANCEMENTS IN EYE CARE: FATHER-SON TEAM RESTORING SIGHT At the height of the pandemic, across most medical specialties, doctors noted a sharp drop in care as patients curbed nonessential visits and procedures out of the fear that a medical appointment could lead to the coronavirus infection. But it wasn’t just dramatic specialties like cancer or heart care that saw collateral damage from ...
-
Clearside Biomedical to Present at the Ophthalmology Futures Retina Forum 2022
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer will present a company overview and participate in an industry panel virtually during the Ophthalmology Futures ...
-
Haymarket Medical Network Launches Ophthalmology Advisor
Haymarket Medical Network today launched Ophthalmology Advisor, a new digital resource that empowers ophthalmology healthcare professionals with comprehensive clinical, surgical, and pharmaceutical information. Ophthalmology Advisor meets the informational and educational needs of ophthalmology specialists by offering the same timely and high quality information that clinicians have come to ...
-
MediPrint™ Ophthalmics Announces Initial Series A Funding Success
SAN DIEGO–(BUSINESS WIRE) (March 15th, 2022) –Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on enhancing vision for life, announces the initial closing of a Series A round that exceeded $2.5 million, including from existing investors. There will be a subsequent close of this round, in Q2 2022, when the round is ...
-
Patent application published covering novel technology to improve contact lens care solutions
CIS Pharma’s new lens care patent application was published. The patent covers the latest developments in the field of contact lens care creating multi-purpose disinfecting solutions, MPDS, with an improved efficacy/safety profile. CIS Pharma’s innovation reduces the trade-off between efficacy and safety, inherent to MPDS that cover the complete contact lens care regimen with just one ...
-
TearLab Corporation Announces Adam Szaronos as President and Chief Executive Officer, and Jim Mazzo as Executive Chairman of the Board
TearLab Corporation, a global ophthalmic diagnostics company marketing point-of-care laboratory testing, today announced that Adam Szaronos has been appointed President and Chief Executive Officer by the company's Board of Directors, effective immediately. Mr. Szaronos has been instrumental in leading teams and bringing innovations to market to address unmet needs throughout eye care. Mr. ...
By SOFIE
-
MediPrint™ Ophthalmics Announces Acceptance and Presentation of Poster at the Upcoming GSLS in Las Vegas
SAN DIEGO–(BUSINESS WIRE)–Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight, announces the acceptance and presentation of a poster highlighting its latest clinical results at the upcoming Global Specialty Lens Symposium (GSLS), a leading eye care conference. The poster spotlights the results ...
-
MediPrint™ Ophthalmics Announces New Corporate Branding and New Website
Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight, announces its new corporate branding and new website. The new corporate logo was designed to better reflect and illustrate the purpose and passion underlying the Company’s goal to use the MediPrint process to help protect sight by printing ...
-
MediPrint™ Ophthalmics Announces Promising Results From Its Primary Market Research
SAN DIEGO–(BUSINESS WIRE)–Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight, announces enlightening findings from its primary market research with optometrists and ophthalmologists related to contact lens drug delivery and its proprietary pipeline of assets. Key learnings from the market ...
-
AbbVie and iSTAR Medical Announce Strategic Alliance for the Treatment of Glaucoma
NORTH CHICAGO, Ill. and WAVRE, BELGIUM, July 20, 2022 – AbbVie (NYSE: ABBV) and iSTAR Medical SA, today announced a strategic transaction to further develop and commercialize iSTAR Medical’s MINIject® device, a next-generation minimally invasive glaucoma surgical (MIGS) device for patients with glaucoma. This complementary alliance will support iSTAR Medical’s development ...
-
Digital Diagnostics and Orbis International announce study to help save sight in Bangladesh
(Coralville, IA.) May 19, 2021 – Digital Diagnostics, developers of IDx-DR, an FDA De Novo-cleared autonomous AI system for the detection of diabetic retinopathy (DR) and diabetic macular edema (DME), and Orbis International, the influential nonprofit dedicated to fighting avoidable blindness around the world, have partnered on a study that will bring high-quality disease detection to ...
-
iSTAR Medical appoints leading glaucoma specialist Prof. Kaweh Mansouri as Chief Medical Officer
WAVRE, Belgium — 6 September 2022: iSTAR Medical, a medtech company delivering breakthrough eye care solutions to patients, today announces the appointment of Dr Kaweh Mansouri as Chief Medical Officer (CMO). Dr Mansouri is a medical and surgical eye specialist, sub-specializing in glaucoma and cataract. Currently a Consultant Ophthalmologist at the Glaucoma Center, Swiss Visio, ...
-
Optos plc, Unveils Silverstone, a Combined Ultra-widefield Retinal Imaging Device and UWF-Guided Swept Source OCT for the Ophthalmic Market
Optos plc, the leading medical retinal imaging company, part of Nikon Corporation, is pleased to announce the launch of Silverstone at the American Academy of Ophthalmology, San Francisco, CA. Silverstone is the first of its kind, combining world-leading ultra-widefield retinal imaging with integrated, image-guided, swept source OCT. Silverstone produces a 200° single capture optomap® ...
By Optos, Inc.
-
iSTAR Medical Expands Commercial Rollout with First MINIject Surgeries in Switzerland
The only commercially available MIGS device currently targeting the supraciliary space now available to patients and surgeons in Switzerland First implantations performed by Prof. Dr Kaweh Mansouri at Swiss Visio, Clinique de Montchoisi, Lausanne and Prof. Dr med. Jan Darius Unterlauft at Inselspital, Bern WAVRE, Belgium — 10 May 2022: iSTAR Medical, a medtech company delivering ...
-
iSTAR Medical shows initial positive progress of US STAR-V trial for MINIject
Pivotal trial of MINIject, STAR-V, now initiated in 13 sites across the US Positive feedback from world-leading glaucoma surgeons involved in the trial MINIject is the only commercially available MIGS device targeting the supraciliary space. Commercial rollout continues following European approval in 2021 WAVRE, Belgium — 12 January 2022: iSTAR Medical, a medtech company delivering ...
-
iSTAR Medical Presents Positive Consistent Results for MINIject Across Three International Glaucoma Trials
Analysis provides further validation of MINIject®’s meaningful and sustained efficacy in open angle glaucoma patients No safety concerns with corneal endothelial health reported across all three trials MINIject® delivers positive, consistent results up to two-year follow-up in patients across Central and South America, Asia and Europe WAVRE, Belgium — 8 June 2022: ...
-
Leo Lens Pharma Expands Its Scientific Advisory Board
SAN DIEGO, CA, USA (Business Wire August 5th, 2020) – Today, Leo Lens Pharma, an emerging San Diego-based pharmaceutical company focused on helping protect sight, announces the expansion of its Scientific Advisory Board (SAB) that now comprises seven world-class eye care professionals, including three ophthalmologists and four optometrists. Leo Lens expanded its SAB with four eye care ...
-
Leo Lens Pharma Excited to Have Its Lead Asset Ready for Human Clinical Evaluation
SAN DIEGO, CA, USA (BUSINESS WIRE June 23, 2020) – Today, Leo Lens Pharma, an emerging San Diego-based pharmaceutical company focused on helping protect sight, is pleased to announce that its lead asset, LL- BMT1, is ready for IND submission and human clinical evaluation. LL-BMT1 is a therapeutic contact lens that delivers preservative-free bimatoprost to the eye to treat glaucoma for one ...
-
Optos wins Artificial Intelligence in Health and Care Award to support the early detection of diabetes in NHS patients
Optos, a Fife based company and a world-leader in the design and manufacturing of advanced retinal imaging technology, has been awarded NHS funding to accelerate the implementation and validation of Artificial Intelligence (AI) to support the early detection of Diabetes related eye-disease into NHS Diabetic Eye Screening practices. The technology uses a machine learning algorithm to analyse ...
By Optos, Inc.
-
Hydrus Microstent Receives Highest Designation of Any MIGS Device as Part of AAO Treatment Guidelines
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, announced today that the American Academy of Ophthalmology (AAO) has designated the Hydrus Microstent as “Level 1, Moderate Quality, Strong Recommendation” — the highest designation of any MIGS device ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you